Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...

Humira is already off-patent and losing ground to rivals in Europe, although AbbVie’s legal defences have so far held fast in the US, preventing competition from biosimilars until 2023.

It can sometimes spread to the face, ears, or scalp ... drugs like Humira (adalimumab) or Enbrel (etanercept) are generally reserved for cases that eventually become plaque psoriasis.

Generalized pustular psoriasis (GPP) is considered a rare and ... These individuals had previously developed a resistance to adalimumab (Humira), another biologic. Despite some reports of success ...

Humira’s success is down to its incredible versatility – an anti-TNF drug, it is approved in a range of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis and Crohn’s ...

and local tolerability data in scalp and body psoriasis In the United States, AD affects approximately 26 million adults and children and psoriasis affects approximately 9 million adults and ...